Extended-state DMT, sometimes shortened to DMTx, is a research method that gives DMT as a controlled, continuous infusion into a vein. A single dose acts within minutes and fades within about half an hour, which makes the experience hard to study. In 2016 Andrew Gallimore and Rick Strassman used pharmacokinetic modelling to propose target-controlled infusion, a technology from anaesthesia, to hold volunteers in a stable state for observation and brain imaging (Gallimore and Strassman, 2016).
Later studies made it work, and revised one of the proposal’s premises. The 2016 model assumed no acute tolerance. In London, 11 volunteers were held in a steady state for 30 minutes; their effects plateaued while blood DMT kept rising (Luan et al., 2024). In Basel, 27 participants’ effects were stable from 30 to 90 minutes despite rising blood levels (Vogt et al., 2023). A second Basel study of 120-minute infusions found that the highest rate tested caused significant anxiety (Erne et al., 2025).
So the method can extend the state in a lab, but the experience does not keep pace with rising blood levels. All of this is small, early research in screened volunteers under medical supervision.
Sources
- Gallimore and Strassman, 2016, Frontiers in Pharmacology: target-controlled infusion model
- Luan et al., 2024, Journal of Psychopharmacology: effects of extended DMT
- Vogt et al., 2023, Translational Psychiatry: intravenous DMT, placebo-controlled
- Erne et al., 2025, Neuropsychopharmacology: continuous DMT infusions
Last checked .